{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:45:49Z","timestamp":1772293549704,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":136,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.idcr.2022.e01514","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T02:37:28Z","timestamp":1653014248000},"page":"e01514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review"],"prefix":"10.1016","volume":"28","author":[{"given":"Tulika","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moni","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rone-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad O.","family":"Almoujahed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharjeel","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.idcr.2022.e01514_bib1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.idcr.2022.e01514_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729901","article-title":"Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review","volume":"24","author":"Bohra","year":"2017","journal-title":"Cancer Control"},{"key":"10.1016\/j.idcr.2022.e01514_bib3","article-title":"Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases","author":"Darcy","year":"2021","journal-title":"J Neurovirol"},{"key":"10.1016\/j.idcr.2022.e01514_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421993684","article-title":"PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy","volume":"14","author":"M\u00f6hn","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.idcr.2022.e01514_bib5","article-title":"Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and\/or hematologic malignancy: a case series of five patients [published online ahead of print, 2021 Jul 1]","volume":"10","author":"Volk","year":"2021","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.idcr.2022.e01514_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab","volume":"29","author":"Focosi","year":"2019","journal-title":"Rev Med Virol"},{"issue":"6","key":"10.1016\/j.idcr.2022.e01514_bib7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13365-020-00899-0","article-title":"Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab","volume":"26","author":"Holmes","year":"2020","journal-title":"J Neurovirol"},{"issue":"3","key":"10.1016\/j.idcr.2022.e01514_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/QAI.0b013e31825a313c","article-title":"Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy","volume":"60","author":"Tan","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.idcr.2022.e01514_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/QAI.0b013e3181fbab9f","article-title":"Identifcation of PD-1as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment","volume":"56","author":"Grabmeier-Pfstershammer","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.idcr.2022.e01514_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000628","article-title":"Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency","volume":"6","author":"K\u00fcpper","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"10.1016\/j.idcr.2022.e01514_bib11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of progressive multifocal leukoencephalopathy with pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.idcr.2022.e01514_bib12","doi-asserted-by":"crossref","unstructured":"M. Mozo Ruiz, N. Rosado Barrasa, D. Tena G\u00f3mez, M. Torralba Gonz\u00e1lez de Suso, Pembrolizumab treatment for progressive multifocal leukoencephalopathy in a patient with Human Immunodeficiency Virus infection Trat con pembrolizumab En Paciente con Infecc por Virus De la inmunodeficiencia Hum Y leucoencefalopat\u00eda multifocal Progres Enferm Infecc Microbiol Clin (Engl Ed), 38, 8, 2020, pp. 396\u2013397 doi:\u00a010.1016\/j.eimc.2019.12.008.","DOI":"10.1016\/j.eimc.2019.12.008"},{"issue":"6","key":"10.1016\/j.idcr.2022.e01514_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000627","article-title":"Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?","volume":"6","author":"Pawlitzki","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.idcr.2022.e01514_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1941874420902872","article-title":"Stabilization of progressive multifocal leukoencephalopathy after pembrolizumab treatment","volume":"10","author":"Kapadia","year":"2020","journal-title":"Neurohospitalist"},{"issue":"4","key":"10.1016\/j.idcr.2022.e01514_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000756","article-title":"Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy","volume":"7","author":"Mahler","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.idcr.2022.e01514_bib16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/ene.14435","article-title":"Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin-2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome","volume":"27","author":"Goereci","year":"2020","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.idcr.2022.e01514_bib17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10072-020-04582-4","article-title":"Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report","volume":"42","author":"St\u00f6gbauer","year":"2021","journal-title":"Neurol Sci"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250922001421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250922001421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:04:48Z","timestamp":1761998688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250922001421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":17,"alternative-id":["S2214250922001421"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2022.e01514","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2022.e01514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01514"}}